Medical Marijuana, Inc. Applauds New Market Opportunities for CBD, United Nations World Health Organization Hosts 40th Expert Committee on Drug Dependence Meeting

Eine Labormitarbeiterin bei einer mikroskopischen Untersuchung. (Symbolbild) © Likoper / iStock / Getty Images Plus / Getty Images http://www.gettyimages.de/

PR Newswire

SAN DIEGO, May 30, 2018

SAN DIEGO, May 30, 2018 /PRNewswire/ -- Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States, announced today that the company applauds the United Nations World Health Organization's Expert Committee on Drug Dependence (ECDD) for focusing its 40^th Annual Meeting on reviewing cannabis and cannabis-related substances next week.

In November 2017, Medical Marijuana, Inc. subsidiary HempMeds® President, Latin America Raul Elizalde spoke at the 39^th Expert Committee on Drug Dependence meeting where he spoke about the therapeutic benefits of cannabidiol (CBD) and shared his story about how CBD helped his daughter Grace become seizure-free.

"We're very excited for the World Health Organization and United Nations to make a final recommendation on CBD products after the findings revealed during this meeting," said Medical Marijuana, Inc. CEO Dr. Stuart Titus. "Though the WHO declared that initial evidence from human and animal studies 'shows that its use could have some therapeutic benefits', which is a very important distinction, we're optimistic that the WHO will soon declare that CBD should not be scheduled as a drug."

Titus continued, "If this prestigious organization agrees that CBD should be sold as a nutritional supplement, it would open up many new opportunities for it to be sold in a variety of health and wellness retail locations around the world. Such a recommendation may influence a number of countries to review their regulations on CBD."

The 40^th meeting of the Expert Committee on Drug Dependence will be held in Geneva, Switzerland, June 4-7, 2018. Members of the committee, including many prestigious doctors, professors and researchers, will discuss and review the entire cannabis plant, cannabis resin, extracts and tinctures of cannabis, Delta-9-tetrahydrocannabidiol (THC) and isomers of THC. Areas of study will include the chemistry, pharmacology, toxicology and therapeutic use of these substances.

For more information about this meeting, please visit http://www.who.int/medicines/access/controlled-substances/ecdd_40_meeting/en/.

About Medical Marijuana, Inc.

ARIVA.DE Börsen-Geflüster

Kurse

Medical Marijuana Inc

0,00205 $

+2,50%

We are a company of firsts®. Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.'s portfolio and investment companies, visit www.medicalmarijuanainc.com.

To see Medical Marijuana, Inc.'s corporate video, click here.

Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.'s shop.

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE

These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.

LEGAL DISCLOSURE

Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.

CONTACT:
Public Relations Contact:
Andrew Hard
Chief Executive Officer CMW Media
P. 858-264-6600
andrew.hard@cmwmedia.com
www.cmwmedia.com

View original content:http://www.prnewswire.com/news-releases/medical-marijuana-inc-applauds-new-market-opportunities-for-cbd-united-nations-world-health-organization-hosts-40th-expert-committee-on-drug-dependence-meeting-300656196.html

SOURCE Medical Marijuana, Inc.

Mehr Nachrichten zur Medical Marijuana Inc Aktie kostenlos abonnieren

E-Mail-Adresse

Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.